Lv31
380 积分 2024-09-10 加入
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
1小时前
已完结
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
1个月前
已完结
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
1个月前
已完结
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
1个月前
已完结
Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients
1个月前
已完结
Decoding the Liver-Heart Axis in Cardiometabolic Diseases
2个月前
已完结
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
2个月前
已完结
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease
2个月前
已完结
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy
3个月前
已完结
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy
3个月前
已完结
皖公网安备34019202002308
